Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Innate Pharma
Study ID
NCT06781983
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Advanced or Metastatic Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • IPH4502 — DRUG
    Part 1 (dose escalation) and Part 2 (dose optimization)

Study Details

This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4

Key Dates

Start date
Jan 24, 2025
Status verified
Jul 2025
Primary completion
Apr 30, 2028
Completion
Apr 30, 2029

Study Design

Enrollment
145 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: IPH4502 Monotherapy

Primary Outcome Measure

Safety and Tolerability [ Time Frame: From time of first dose through treatment period, including the follow-up: up to 24 months ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
Massachusetts General Hospital - BostonBostonMassachusetts02114
Leon Pappas, MD (PRINCIPAL_INVESTIGATOR)
John Theurer Cancer CenterHackensackNew Jersey07601
Martin Gutierrez, MD (PRINCIPAL_INVESTIGATOR)
Mount Sinai Tisch Cancer CenterNew YorkNew York10029
Thomas Marron, MD (PRINCIPAL_INVESTIGATOR)
NEXT Oncology - DallasDallasTexas75039
Shiraj Sen, MD
NEXT Oncology - VirginiaFairfaxVirginia22031
Alex Spira, MD

Find similar trials in Boston, MA

By research site
Massachusetts General Hospital - Boston· Boston, MAJohn Theurer Cancer Center· Hackensack, NJMount Sinai Tisch Cancer Center· New York, NYNEXT Oncology - Dallas· Dallas, TXNEXT Oncology - Virginia· Fairfax, VA

Related Studies